{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:32:13Z","timestamp":1786984333214,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.amjcard.2020.04.026","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T02:58:53Z","timestamp":1587524333000},"page":"64-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout"],"prefix":"10.1016","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9805-4562","authenticated-orcid":false,"given":"Anthony P.","family":"Carnicelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Clare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0279-9093","authenticated-orcid":false,"given":"Karen","family":"Chiswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Lytle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7480-3656","authenticated-orcid":false,"given":"Magnus","family":"Bjursell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira","family":"Perl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0163-418X","authenticated-orcid":false,"given":"Katarina","family":"Hedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Pagidipati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreekanth","family":"Vemulapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Roe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Mentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2020.04.026_bib0001","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10741-012-9322-2","article-title":"Uric acid in heart failure: a biomarker or therapeutic target?","volume":"18","author":"Kaufman","year":"2013","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0002","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0003","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.amjcard.2017.06.057","article-title":"Prevalence of Hyperuricemia in Patients With Acute Heart Failure With Either Reduced or Preserved Ejection Fraction","volume":"120","author":"Palazzuoli","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0004","article-title":"Validity of heart failure diagnoses in administrative databases: a systematic review and meta-analysis","volume":"9","author":"McCormick","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0005","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0006","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/1471-2369-14-164","article-title":"The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality","volume":"14","author":"Gustafsson","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0007","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1751-7133.2011.00259.x","article-title":"Hyperuricemia and the echocardiographic measures of myocardial dysfunction","volume":"18","author":"Krishnan","year":"2012","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0008","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/archinte.164.14.1546","article-title":"Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study","volume":"164","author":"Niskanen","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0009","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0010","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jacc.2013.09.039","article-title":"Heart failure with preserved ejection fraction: comparison of patients with and without angina pectoris (from the Duke Databank for Cardiovascular Disease)","volume":"63","author":"Mentz","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0011","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ahj.2017.02.023","article-title":"An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome","volume":"187","author":"Pagidipati","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0012","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/CIRCHEARTFAILURE.108.797662","article-title":"Hyperuricemia and incident heart failure","volume":"2","author":"Krishnan","year":"2009","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0013","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","article-title":"Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study","volume":"131","author":"Givertz","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0014","doi-asserted-by":"crossref","first-page":"H1123","DOI":"10.1152\/ajpheart.00533.2015","article-title":"Relationship of hyperuricemia with mortality in heart failure patients with preserved ejection fraction","volume":"309","author":"Shimizu","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0015","article-title":"Prognostic value of serum uric acid in hospitalized heart failure patients with preserved ejection fraction (From the Japanese Nationwide Multicenter Registry)","author":"Kobayashi","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0016","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1388-9842(02)00086-7","article-title":"The management of hyperuricemia and gout in patients with heart failure","volume":"4","author":"Spieker","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2011-000282","article-title":"Gout and the risk for incident heart failure and systolic dysfunction","volume":"2","author":"Krishnan","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0018","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009328","article-title":"Association of gout with long-term cardiovascular outcomes among patients with obstructive coronary artery disease","volume":"7","author":"Pagidipati","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0019","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1161\/CIRCULATIONAHA.106.651117","article-title":"High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid","volume":"114","author":"George","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0020","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1161\/hc4501.098928","article-title":"Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy","volume":"104","author":"Cappola","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0021","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/01.RES.85.5.437","article-title":"Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure","volume":"85","author":"Ekelund","year":"1999","journal-title":"Circ Res"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0022","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1161\/01.CIR.0000144303.24894.1C","article-title":"Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug?","volume":"110","author":"Engberding","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0023","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12872-017-0513-6","article-title":"Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes","volume":"17","author":"Singh","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0024","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/archinternmed.2010.198","article-title":"Gout, allopurinol use, and heart failure outcomes","volume":"170","author":"Thanassoulis","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0025","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4103\/0975-3583.74262","article-title":"Allopurinol and global left myocardial function in heart failure patients","volume":"1","author":"Nasr","year":"2010","journal-title":"J Cardiovasc Dis Res"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0026","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/hrt.2004.040477","article-title":"Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure","volume":"91","author":"Gavin","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0027","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1161\/CIRCULATIONAHA.115.016379","article-title":"Xanthine oxidase inhibitors in heart failure: where do we go from here?","volume":"131","author":"Tamariz","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0028","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.cardfail.2019.07.071","article-title":"Uric-acid lowering treatment by a xanthine oxidase inhibitor improved the diastolic function in patients with hyperuricemia","volume":"25","author":"Ogino","year":"2019","journal-title":"Journal of Cardiac Failure"},{"key":"10.1016\/j.amjcard.2020.04.026_bib0029","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3899\/jrheum.081195","article-title":"Poor validation of medical record ICD-9 diagnoses of gout in a veterans affairs database","volume":"36","author":"Malik","year":"2009","journal-title":"J Rheumatol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914920303957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914920303957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:34:45Z","timestamp":1757572485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914920303957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":29,"alternative-id":["S0002914920303957"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2020.04.026","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2020.04.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}